{"id":70719,"date":"2026-05-12T09:49:37","date_gmt":"2026-05-12T09:49:37","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70719"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"follistatin-344","status":"publish","type":"product","link":"https:\/\/medsbase.com\/it\/product\/follistatin-344\/","title":{"rendered":"Follistatin 344"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Risposta rapida \u2014 Cos'\u00e8 la Follistatina 344?<\/h3>\n<p style=\"margin: 0;\"><strong>Follistatin 344<\/strong> (FST-344) is a 344-amino-acid recombinant glycoprotein and the longer of the two principal splice isoforms of human follistatin. It is the canonical endogenous antagonist of myostatin (GDF-8) and activin, used in published studies investigating muscle hypertrophy, sarcopenia, muscular dystrophy preclinical models, and the activin\/myostatin signalling axis. Supplied in 1\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Cosa ottieni con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/it\/reviews\/\">recensioni dei clienti<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ogni ordine \u00e8 coperto dalla nostra <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica di Garanzia di Rispedizione<\/strong><\/a> \u2014 se il tuo pacco non arriva entro 20 giorni lavorativi, lo rispediamo.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifiche<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Dettaglio<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Numero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">80449-31-6 (follistatin)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Glicoproteina ricombinante (isoforma di splicing FST-344 a 344 amminoacidi della follistatina umana)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~37 kDa (forma glicosilata matura; intervallo osservato ~38\u201342 kDa su SDS-PAGE a seconda dello stato di glicosilazione)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Struttura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Dominio di legame all'eparina N-terminale seguito da tre domini follistatin (FSD1, FSD2, FSD3) ciascuno contenente un sottodominio simile all'EGF e uno simile al Kazal; ricco di cisteina, con multipli legami disolfuro intramolecolari<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Proteina ricombinante liofilizzata (da bianca a biancastra)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Purezza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226595% (verificato con HPLC, COA su richiesta)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Conservazione<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizzato: 2\u20138\u00a0\u00b0C (frigorifero) per lo stock di lavoro; \u221220\u00a0\u00b0C per lo stoccaggio a lungo termine di fiale non aperte. Ricostituito: 2\u20138\u00a0\u00b0C, utilizzare entro ~30 giorni. Proteggere dalla luce. Non congelare e scongelare la soluzione ricostituita \u2014 le proteine ricombinanti sono particolarmente sensibili alla denaturazione da congelamento-scongelamento.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e0<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Acqua batteriostatica (consigliata) o acqua sterile per finestre di utilizzo pi\u00f9 brevi. Proteina carrier (BSA, 0,1%) opzionale per diluizioni di lavoro per minimizzare le perdite per adsorbimento.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Cos'\u00e8 la Follistatina 344?<\/h2>\n<p><strong>Follistatin 344<\/strong> (often abbreviated FST-344) is a recombinant 344-amino-acid glycoprotein and the longer of the two principal physiological splice isoforms of human follistatin \u2014 the other being FST-288, a shorter 288-amino-acid membrane-bound form. Endogenous follistatin was first isolated in 1987 from porcine ovarian follicular fluid by Esch et al. (PNAS) and Robertson et al. (Biochem Biophys Res Commun) as a factor that selectively inhibits follicle-stimulating hormone (FSH) secretion, which gave the protein its name. The mechanistic role \u2014 high-affinity binding and neutralisation of activin and myostatin \u2014 was characterised over the subsequent decade. FST-344 is a circulating, secreted isoform with a heparin-binding N-terminal domain followed by three cysteine-rich follistatin domains (FSD1, FSD2, FSD3) that together form the activin- and myostatin-binding surface. The recombinant 344-residue chain has a mature mass of approximately 37\u00a0kDa, with apparent molecular weight on SDS-PAGE varying between 38 and 42\u00a0kDa depending on the glycosylation state of the recombinant expression system. CAS number 80449-31-6. The protein is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Follistatin is <strong>dalla FDA, EMA, MHRA o da qualsiasi altro importante regolatore per uso terapeutico umano. Il DSIP di grado di ricerca venduto qui \u00e8 fornito<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For related anabolic and growth-axis studies, see our <a href=\"https:\/\/medsbase.com\/it\/igf-1-lr3\/\">IGF-1 LR3<\/a> pagina prodotto. <\/p>\n<h2>Meccanismo d'azione \u2014 Antagonismo del percorso della Miostatina e dell'Attivina<\/h2>\n<p>What makes follistatin 344 mechanistically unique among muscle-studies proteins is its <strong>profilo di legame multi-target<\/strong> across the TGF-\u03b2 superfamily \u2014 each ligand-binding event contributing to the observed hypertrophic and growth-modulatory phenotype in published studies:<\/p>\n<ul>\n<li><strong>Sequestro della Miostatina (GDF-8) \u2014 asse dell'ipertrofia muscolare<\/strong> \u2014 Follistatin binds myostatin (also called GDF-8) with high affinity, sterically blocking its interaction with the activin type II receptor (ActRIIB). Myostatin is the canonical endogenous negative regulator of muscle growth: knockout mice develop dramatic muscle hypertrophy (the &#8220;double-muscling&#8221; phenotype), and naturally myostatin-deficient cattle breeds (Belgian Blue, Piedmontese) show the same effect. By neutralising myostatin, follistatin removes the brake on muscle protein synthesis, producing hypertrophy in study models. This is the most-cited mechanism in the muscle-literature.<\/li>\n<li><strong>Sequestro di Activina A e B \u2014 segnalazione riproduttiva, ovarica e ipofisaria<\/strong> \u2014 Follistatin&#8217;s original characterised function was binding and neutralising activin, a related TGF-\u03b2 superfamily member that stimulates FSH secretion from the pituitary, drives ovarian follicle development, and acts as a regulator of many cell types. By binding activin A, B, and AB heterodimers, follistatin shifts the activin\/inhibin balance in study models and modulates downstream Smad2\/Smad3 signalling.<\/li>\n<li><strong>Modulazione di GDF-11 e della pi\u00f9 ampia superfamiglia TGF-\u03b2<\/strong> \u2014 Follistatin also binds GDF-11 (closely related to myostatin) with somewhat lower affinity, alongside other TGF-\u03b2 superfamily members. GDF-11 is increasingly studied in aging studies because its endogenous levels decline with age and its modulation is implicated in age-related cardiac and CNS phenotypes. Follistatin 344 is one of the principal tools for investigating this axis.<\/li>\n<\/ul>\n<p>The three follistatin domains (FSD1, FSD2, FSD3) each contribute to the binding profile: FSD1 contains the principal myostatin-binding surface, FSD2 the principal activin-binding surface, and FSD3 contributes both binding affinity and structural stability. The heparin-binding N-terminal domain distinguishes the splice variants \u2014 FST-288 binds heparan sulfate strongly and is largely membrane-anchored, while FST-344 (this isoform) circulates more freely. This distinction is mechanistically relevant in study models studying systemic vs local follistatin effects. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Follistatin 344 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Muscle hypertrophy and protein synthesis studies<\/strong> \u2014 modelli di ipertrofia in topo e ratto inclusi studi di consegna genica AAV-follistatina (Kota et al., Sci Transl Med 2009); area della sezione trasversa specifica per tipo di fibra, peso umido del muscolo, generazione di forza<\/li>\n<li><strong>Modelli preclinici di distrofia muscolare<\/strong> \u2014 modello murino mdx della distrofia muscolare di Duchenne; capacit\u00e0 funzionale, rigenerazione delle fibre, preservazione muscolare indipendente dalla distrofina<\/li>\n<li><strong>Sarcopenia e perdita muscolare legata all'et\u00e0<\/strong> \u2014 aged-mouse muscle phenotypes, anabolic resistance, fibre-type-shift studies<\/li>\n<li><strong>Cancer cachexia studies<\/strong> \u2014 modelli di cachessia in topi portatori di tumore, preservazione della composizione corporea, rapporto massa magra\/massa grassa<\/li>\n<li><strong>Reproductive endocrinology studies<\/strong> \u2014 FSH suppression, ovarian follicle development, granulosa-cell biology, pituitary-gonadal-axis studies<\/li>\n<li><strong>Activin pathway studies<\/strong> \u2014 Smad2\/Smad3 signalling, EMT in cancer models, fibrosis studies, hepatic regeneration<\/li>\n<li><strong>Aging and GDF-11 axis studies<\/strong> \u2014 cardiac and CNS aging phenotypes, parabiosis-related studies, GDF-11\/myostatin balance with aging<\/li>\n<li><strong>Comparative anabolic studies<\/strong> \u2014 confronto diretto con <a href=\"https:\/\/medsbase.com\/it\/igf-1-lr3\/\">IGF-1 LR3<\/a> (parallel anabolic pathway via IGF-1 receptor) for combined or comparative hypertrophy studies.<\/li>\n<\/ul>\n<p>For broader context on where follistatin 344 fits within the anabolic and growth-axis studies landscape, see <a href=\"https:\/\/medsbase.com\/it\/igf-1-lr3\/\">IGF-1 LR3<\/a> come il comparatore canonico dell'asse IGF, <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for GHRH-axis growth studies, and <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> for shorter-acting GHRH use. Browse the full <a href=\"https:\/\/medsbase.com\/it\/peptides\/\">catalogo peptidi<\/a> per composti correlati. <\/p>\n<h2>Concentrazioni e Dosaggi Disponibili<\/h2>\n<p>MedsBase stocks Follistatin 344 in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosaggio per Flaconcino<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso d'Uso Tipico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dimensioni della Confezione<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 muscle hypertrophy and activin\/myostatin axis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Follistatin 344 is a 37\u00a0kDa recombinant glycoprotein supplied at \u226595% HPLC purity. The 1\u00a0mg vial format is the standard strength for in vivo and in vitro work \u2014 one vial reconstituted with 1.0\u00a0mL bacteriostatic water yields a 1\u00a0mg\/mL working concentration sufficient for many weeks of cell-culture protocols or several rodent-protocol injections. <\/p>\n<h2>Confronto - Follistatina 344 vs IGF-1 LR3<\/h2>\n<p>La Follistatina 344 e <a href=\"https:\/\/medsbase.com\/it\/igf-1-lr3\/\">IGF-1 LR3<\/a> are the two most-cited recombinant anabolic proteins in current hypertrophy studies. They act on entirely different pathways \u2014 follistatin by removing the myostatin brake on muscle growth, IGF-1 LR3 by directly stimulating the IGF-1 receptor and downstream Akt\/mTOR protein synthesis \u2014 which makes them mechanistically complementary in protocols. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Follistatin 344<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">IGF-1 LR3<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Lunghezza<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">344 aminoacidi (glicoproteina ricombinante)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">83 aminoacidi (IGF-1 modificato)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecolare<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~37 kDa<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~9 kDa<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meccanismo primario<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sequestro di miostatina\/attivina<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonismo del recettore IGF-1 \u2192 Akt\/mTOR<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Modalit\u00e0 d'effetto<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Disinibizione (rimuove il freno alla crescita)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Stimolazione anabolica diretta<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosaggio tipico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013100 mcg, 1\u20133 volte a settimana<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">20\u201360 mcg, giornalmente<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ipertrofia muscolare globale, modelli di distrofia<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Local hypertrophy, regenerative anabolic studies<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Stacking<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Commonly co-administered with IGF-1 LR3 in hypertrophy studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Comunemente co-somministrato con follistatina 344<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Because the two proteins act on fundamentally different anabolic axes \u2014 follistatin removes the myostatin brake while IGF-1 LR3 directly stimulates protein synthesis \u2014 combined administration is commonly used in study models exploring maximal hypertrophic response. For studies interested in the myostatin pathway specifically, follistatin 344 is the canonical first choice; for IGF\/Akt\/mTOR anabolic studies, IGF-1 LR3 is the canonical tool. <\/p>\n<h2>Conservazione e ricostituzione<\/h2>\n<p><strong>Prima della ricostituzione:<\/strong> conservare i flaconcini liofilizzati refrigerati a 2\u20138 \u00b0C nella confezione originale per lo stock di lavoro a breve termine. Per lo stoccaggio a lungo termine non aperto, congelare a \u221220 \u00b0C. La follistatina 344 liofilizzata \u00e8 stabile sotto refrigerazione fino a 12 mesi e a \u221220 \u00b0C fino a 24 mesi \u2014 un po' meno dei piccoli peptidi sintetici perch\u00e9 la glicoproteina ricombinante pi\u00f9 grande \u00e8 pi\u00f9 suscettibile a deamidazione e ossidazione nel tempo. Evitare cicli di congelamento-scongelamento sulla polvere liofilizzata. <strong>Procedura di ricostituzione:<\/strong> iniettare acqua batteriostatica lungo la parete laterale del flaconcino di peptide (non direttamente sulla torta liofilizzata). Per un flaconcino da 1 mg, 1,0 mL di acqua batteriostatica producono una concentrazione di lavoro di 1 mg\/mL. Agitare delicatamente \u2014 non <strong>not<\/strong> conservare refrigerato a 2\u20138 \u00b0C e utilizzare entro 30 giorni per una stabilit\u00e0 ottimale. Non congelare la soluzione ricostituita \u2014 le glicoproteine ricombinanti sono particolarmente sensibili alla denaturazione da congelamento-scongelamento, che produce aggregazione e perdita di attivit\u00e0. Scartare qualsiasi flaconcino che presenti torbidit\u00e0, precipitato o scolorimento. <strong>Dopo la ricostituzione:<\/strong> conservare in frigorifero a 2\u20138 \u00b0C e utilizzare entro 30 giorni per una stabilit\u00e0 ottimale. Non congelare la soluzione ricostituita \u2014 le glicoproteine ricombinanti sono particolarmente sensibili alla denaturazione da congelamento-scongelamento, che provoca aggregazione e perdita di attivit\u00e0. Scartare qualsiasi flaconcino che presenti torbidit\u00e0, precipitato o cambiamento di colore. <\/p>\n<h2 id=\"faqs\">Domande frequenti<\/h2>\n<h3>What is Follistatin 344 used for in studies?<\/h3>\n<p>Follistatin 344 is used in studies investigating muscle hypertrophy, muscular dystrophy preclinical models, sarcopenia, cancer cachexia, the activin\/myostatin\/GDF-11 signalling axis, reproductive endocrinology (FSH suppression, ovarian follicle development), and aging-related phenotypes. It is the canonical tool for myostatin pathway antagonism. The pharmaceutical-grade follistatin 344 sold here is <strong>not<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Qual \u00e8 la differenza tra Follistatina 344 e Follistatina 315?<\/h3>\n<p>FST-344 \u00e8 l'isoforma prodotto genico a 344 amminoacidi che include il peptide segnale; FST-315 \u00e8 la stessa proteina dopo il taglio del peptide segnale durante la secrezione (quindi FST-315 \u00e8 la forma matura circolante di FST-344). Entrambi i sistemi di nomenclatura compaiono in letteratura e si riferiscono alla stessa isoforma biologica. Entrambi differiscono sostanzialmente da FST-288, che \u00e8 un'isoforma pi\u00f9 corta derivante da splicing alternativo con un legame pi\u00f9 forte all'eparan solfato e una localizzazione prevalentemente legata alla membrana. <\/p>\n<h3>In cosa differisce la Follistatina 344 dall'IGF-1 LR3?<\/h3>\n<p>Both are recombinant anabolic proteins used in muscle hypertrophy studies, but they target different pathways. Follistatin 344 is a 344-amino-acid glycoprotein that binds and sequesters myostatin and activin \u2014 it works by removing the endogenous brake on muscle growth. IGF-1 LR3 is an 83-amino-acid modified IGF-1 analog that directly agonises the IGF-1 receptor and activates Akt\/mTOR protein synthesis. The two are mechanistically complementary and frequently co-administered in studies. <\/p>\n<h3>What is the typical Follistatin 344 dose?<\/h3>\n<p>Published preclinical protocols typically use 10\u2013100\u00a0mcg per administration in rodent models, given 1\u20133 times weekly for 4\u201312 week cycles. Gene-delivery studies using AAV-follistatin produces tissue-localised concentrations that are difficult to compare directly to systemic-protein dosing. A 1\u00a0mg vial reconstituted with 1.0\u00a0mL bacteriostatic water yields 1\u00a0mg\/mL \u2014 0.01\u00a0mL equals 10\u00a0mcg, 0.1\u00a0mL equals 100\u00a0mcg. <\/p>\n<h3>La Follistatina 344 \u00e8 approvata dalla FDA?<\/h3>\n<p>No. Follistatin 344 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. AAV-follistatin gene therapy has been investigated in clinical trials for muscular dystrophy (e.g., Becker muscular dystrophy, inclusion body myositis) but is not FDA-approved. <\/p>\n<h3>Come va conservata la Follistatina 344?<\/h3>\n<p>Flaconcini liofilizzati: conservare in frigorifero a 2\u20138 \u00b0C per scorte di lavoro a breve termine, o a \u221220 \u00b0C per lo stoccaggio a lungo termine di flaconcini non aperti. Soluzione ricostituita: conservare in frigorifero a 2\u20138 \u00b0C, utilizzare entro 30 giorni. Non congelare la soluzione ricostituita \u2014 le glicoproteine ricombinanti sono particolarmente sensibili alla denaturazione da congelamento-scongelamento. Proteggere sempre dalla luce diretta. Si consiglia l'uso di una proteina carrier (BSA allo 0,1%) per diluizioni di lavoro inferiori a 100 mcg\/mL. <\/p>\n<h3>Come si ricostituisce il Follistatin 344?<\/h3>\n<p>Seguire la procedura di ricostituzione sopra indicata. Aggiungere acqua batteriostatica lungo la parete laterale del flaconcino (non direttamente sulla polvere liofilizzata), agitare delicatamente e attendere 5\u201310 minuti per la completa dissoluzione. Non <strong>not<\/strong> agitare vigorosamente il flaconcino \u2014 una agitazione vigorosa pu\u00f2 denaturare le proteine ricombinanti e causare aggregazione. Una soluzione correttamente ricostituita \u00e8 limpida e incolore. Per un flaconcino da 1 mg + 1,0 mL di diluente, la concentrazione di lavoro \u00e8 di 1 mg\/mL. <\/p>\n<h3>Perch\u00e9 la specifica di purezza \u00e8 del 95% anzich\u00e9 del 99%?<\/h3>\n<p>Recombinant glycoproteins like follistatin 344 cannot achieve the \u226599% HPLC purity standard typical of small synthetic peptides because of the inherent heterogeneity of glycosylation in any recombinant expression system \u2014 different glycoforms appear as related peaks on HPLC that are not impurities but isoforms of the target protein. \u226595% HPLC purity is the standard pharmaceutical-grade specification for follistatin 344 and similar recombinant glycoproteins. SDS-PAGE typically shows a single band with the expected 38\u201342\u00a0kDa apparent mass range. <\/p>\n<h3>Quali dosaggi sono disponibili su MedsBase?<\/h3>\n<p>MedsBase carries Follistatin 344 in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at \u226595% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Can Follistatin 344 and IGF-1 LR3 be stacked in studies?<\/h3>\n<p>Yes. Follistatin 344 and IGF-1 LR3 act on fundamentally different anabolic axes (myostatin antagonism vs IGF-1 receptor agonism) and are frequently co-administered in study models exploring maximal hypertrophic response. The two are mechanistically complementary rather than redundant, and combined-protocol literature describes additive or synergistic effects on muscle fibre cross-sectional area. <\/p>\n<h3>Does Follistatin 344 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented tolerability at typical doses, with the main on-target effect being muscle hypertrophy. Off-target findings include modulation of FSH and ovarian function (because activin signalling is suppressed) and potential effects on hepatic regeneration and pituitary regulation due to follistatin&#8217;s role in broader TGF-\u03b2 superfamily signalling. Systemic follistatin-protein dosing has different exposure characteristics than tissue-localised AAV-gene-delivery approaches. <\/p>\n<h3>Qual \u00e8 l'emivita del Follistatin 344?<\/h3>\n<p>In preclinical studies, recombinant follistatin 344 has a plasma half-life of approximately 1\u20133 hours following intravenous administration, reflecting its size (37\u00a0kDa, above the renal filtration cutoff) and binding to circulating ligands. Tissue half-life is considerably longer because follistatin remains bound to its captured myostatin and activin targets, sequestering them away from receptors. Gene-delivery approaches produce a far longer effective duration of action because tissue expression continues over weeks to months. <\/p>\n<h3>How long does Follistatin 344 take to show effects in preclinical studies?<\/h3>\n<p>Gli effetti di ipertrofia muscolare nei protocolli di iniezione proteica su topi e ratti diventano tipicamente statisticamente significativi dopo 2\u20134 settimane di somministrazione settimanale e continuano ad accumularsi fino a 8\u201312 settimane. Gli effetti sull'asse activina\/FSH sugli endpoint riproduttivi possono essere rilevati entro pochi giorni dalla somministrazione. I protocolli di consegna genica (AAV-follistatin) mostrano un'ipertrofia muscolare misurabile entro 4\u20136 settimane dall'iniezione e continuano a svilupparsi per mesi. <\/p>\n<h3>Posso ordinare Follistatin 344 per la spedizione internazionale?<\/h3>\n<p>S\u00ec. MedsBase spedisce Follistatin 344 in tutto il mondo dalla nostra rete dedicata di spedizione di peptidi. Gli ordini contenenti solo peptidi si qualificano per il nostro servizio di spedizione peptidi autonomo. Tutti gli ordini vengono spediti in imballaggi a temperatura controllata con tracciamento completo e sono coperti dal nostro <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\">Politica di Garanzia di Rispedizione<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Anabolic, Growth-Axis, and Muscle Studies<\/h2>\n<ul>\n<li><a href=\"\/it\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Long-arginine recombinant IGF-1 analog \u2014 direct IGF-1R agonist for Akt\/mTOR studies<\/li>\n<li><a href=\"\/it\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth hormone axis support<\/li>\n<li><a href=\"\/it\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse support<\/li>\n<li><a href=\"\/it\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Agonista selettivo della grelina \u2014 pulso pulito di GH senza cortisolo\/prolattina<\/li>\n<li><a href=\"\/it\/tb-500\/\"><strong>TB-500 (Thymosin Beta-4)<\/strong><\/a> \u2014 Systemic healing fragment \u2014 muscle and cardiac recovery<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Approfondimenti<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore anabolic and growth-axis peptides<\/strong><\/p>\n<p style=\"margin: 0;\">Sfoglia l'intera <a href=\"https:\/\/medsbase.com\/it\/peptides\/\"><strong>catalogo peptidi<\/strong><\/a>, con composti correlati tra cui <a href=\"https:\/\/medsbase.com\/it\/igf-1-lr3\/\">IGF-1 LR3<\/a> for direct IGF-receptor anabolic studies, <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for long-acting GHRH use, and <a href=\"https:\/\/medsbase.com\/it\/tb-500\/\">TB-500<\/a> for systemic muscle and tissue recovery.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Glicoproteina ricombinante 344-aa<br \/>\n\u2705 Antagonista della via di Myostatin &amp; activin<br \/>\n\u2705 Muscle hypertrophy compound<br \/>\n\u2705 Modelli preclinici di distrofia muscolare<br \/>\n\u2705 Purezza \u226595% HPLC, COA su richiesta<\/p>\n<p><strong>Follistatin 344<\/strong> \u00e8 una proteina ricombinante.<\/p>","protected":false},"featured_media":70949,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6276,5441],"class_list":["post-70719","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-follistatin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product\/70719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/comments?post=70719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media\/70949"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media?parent=70719"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_brand?post=70719"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_cat?post=70719"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_tag?post=70719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}